Melanoma Survivorship Feasibility Study
Research type
Research Study
Full title
Feasibility study assessing the long-term effects of systemic therapy on patients with stage III metastatic melanoma: The MELISSA Study.
IRAS ID
319887
Contact name
Marc Moncrieff
Contact email
Sponsor organisation
Norfolk & Norwich University Hospital Foundation NHS Trust
Duration of Study in the UK
2 years, 0 months, 0 days
Research summary
Patients with primary cutaneous melanoma (malignant mole/skin cancer) often are diagnosed with spread of their tumour to the lymph glands, using a staging technique called sentinel node biopsy. The modern of care is to recommend a 12-month course of systemic drug therapy, which can have major side-effects. The incidence of these side effects and the long-term impact of the treatments is largely unknown. In particular the psychological ramifications of completing the treatment are also unknown. Accordingly, it is challenging for cancer centres to plan how to meet the needs of these high-risk cancer patients in the post-treatment observation phase, both physically and psychologically.
The aim of this research is to undertake a feasibility study to determine both the level and extent of the psychological and physical needs of these patients in the setting of a single site, tertiary referral cancer service. If the results are indicative of unmet need, these data will then inform a much larger, UK-wide study, which will be planned separately at a future date.REC name
London - Hampstead Research Ethics Committee
REC reference
23/PR/1036
Date of REC Opinion
4 Dec 2023
REC opinion
Further Information Favourable Opinion